Invacare Declares Quarterly Dividend

ELYRIA, Ohio--(BUSINESS WIRE)-- The Board of Directors of Invacare Corporation (NYSE: IVC) announced that it declared a cash dividend of $.0125 per share on its common shares payable January 17, 2019 to shareholders of record on January 4, 2019.

Invacare Corporation (NYSE: IVC) is a leading manufacturer and distributor in its markets for medical equipment used in non-acute care settings. At its core, the company designs, manufactures and distributes medical devices that help people to move, breathe, rest and perform essential hygiene. The company provides clinically complex medical device solutions for congenital (e.g., cerebral palsy, muscular dystrophy, spina bifida), acquired (e.g., stroke, spinal cord injury, traumatic brain injury, post-acute recovery, pressure ulcers) and degenerative (e.g., ALS, multiple sclerosis, chronic obstructive pulmonary disease (COPD), age-related, bariatric) ailments. The company's products are important parts of care for people with a wide range of challenges, from those who are active and involved in work or school each day and may need additional mobility or respiratory support, to those who are cared for in residential care settings, at home and in rehabilitation centers. The company sells its products principally to home medical equipment providers with retail and e-commerce channels, residential care operators, dealers and government health services in North America, Europe and Asia/Pacific. For more information about the company and its products, visit Invacare's website at www.invacare.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181129005797/en/

Investor Inquiries:
Lois Lee
[email protected]
(440) 329-6435

Source: Invacare Corporation

You May Also Be Interested In

• 49NORTH RELEASES GLOBAL PROCEDURE DESIGNER, A PROVEN INSTRUMENT FLIGHT PROCEDURE DESIGN SOLUTION REFRESHED FOR COMPLIANCE WITH LATEST REGULATIONS
• The Anthem Hotel Debuts the "Soccer Legends Suite" Celebrating U.S. Soccer Culture
• Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress